DNA replication stress is a predominant cause of genome instability, a driver of tumorigenesis and malignant progression. Nucleoside analog-type chemotherapeutic drugs introduce DNA damage and exacerbate DNA replication stress in tumor cells. However, the mechanisms underlying tumor cytotoxicity triggered by the drugs are not fully understood.
INTRODUCTION
Accurate DNA replication is fundamental to faithful genome duplication and cellular proliferation (1) . Obstacles that perturb DNA replication process induce cellular stress termed DNA replication stress (DRS). Tumor cells often lose control mechanisms of DNA replication with sustained proliferation signaling, which leads to DNA damage and chronic DRS (2) . Conventional chemotherapy exerts its cytotoxic effects by introducing DNA damage and simultaneously promotes DRS by perturbing the DNA replication process (3) .
DRS induced by chemotherapy triggers the activation of cellular response pathways for survival in tumor cells; however, loss or suppression of the stress response can increase the susceptibility of tumor cells to catastrophic failure of proliferation. Thus, exploiting DRS is a feasible approach for cancer therapy (4, 5) .
DRS triggers various cellular responses in tumor cells. DRS activates ataxia telangiectasia
and Rad3-related (ATR) kinase, which is recruited to replication protein A (RPA)-coated single-stranded DNA (ssDNA) at the stalled replication fork and transduces signals to numerous downstream targets (e.g. Chk1 is the main effector kinase) via phosphorylation to activate the S phase checkpoint (6) . Thus, ATR and Chk1 preserve genome integrity by stabilizing the stalled fork and preventing origin firing (6, 7) . DRS also activates the Fanconi anemia (FA) pathway, which is a biochemical network that contributes to DNA repair and replication (8) . FA pathway activation, which is triggered by the ATR-dependent phosphorylation of FancI, results in FancD2 monoubiquitination (9, 10) . In cases of moderate DRS, however, tumor cells can escape the S phase checkpoint and proceed to G2 and M phases with under-replicated DNA (UR-DNA) at hard-to-replicate DNA regions, such as common fragile sites (CFSs) (11) . The UR-DNAs form ultrafine DNA bridges (UFBs) at anaphase (12) and induce genome instability phenotypes, such as lagging chromosomes and micronuclei (13) . Moreover, chronic exposure to moderate DRS activates p53 and induces cellular senescence-like growth arrest (14) . Cellular senescence in tumor cells is also induced by anticancer chemotherapy and improves long-term outcomes (15) .
Nucleoside analog-type chemotherapeutic drugs are structurally similar antimetabolites with a broad range of action, and they are clinically active in both solid tumors and hematological malignancies (16) . Nucleoside analogs are efficiently incorporated into the cytoplasm of tumor cells, rapidly phosphorylated to triphosphate forms, and incorporated into DNA during normal DNA synthesis by replicative DNA polymerases. Trifluridine (FTD) is a fluorinated thymidine analog included in the clinically-approved chemotherapeutic drug called trifluridine/tipiracil (FTD/TPI; also named TAS-102) (17) (18) (19) (20) . FTD is massively incorporated into DNA without detectable DNA strand breaks, induces the phosphorylation of Chk1 at serine 345 (pS345 Chk1), a specific site phosphorylated by ATR kinase upon DRS (6) , and activates the p53-p21 pathway, leading to sustained cell cycle arrest at the phase with 4N DNA content (21) . However, the mechanism underlying the induction of DRS by FTD and its contribution to subsequent cell fate decisions remains to be fully elucidated.
To our knowledge, this is the first study to demonstrate that FTD, as a nucleoside analogue, delays DNA replication in vitro. At the cellular level, FTD stalled replication forks and subsequently generated DNA lesions including ssDNA. This led tumor cells to activate the p53-p21 pathway, skip mitosis, and fall into the persistent growth arrest characterized as cellular senescence. On the other hand, p53 knock-out tumor cells showed aberrant mitosis with severely impaired sister chromatid separation that elicited apoptotic cell death. These data indicate that DRS induced by FTD treatment triggers tumor cytotoxicity by determining tumor cell fate according to p53 status.
MATERIALS AND METHODS

Cell culture and reagents
HCT-116 cells were purchased from American Type Culture Collection in 2011. DLD1 cells were provided by Taiho Pharmaceutical Co. Ltd. (22) . A549 cells were provided by Dr. M.
Takeshita (Kyushu University) (21) . All cells were authenticated by short tandem repeat analysis and confirmed negative for Mycoplasma infection with the MycoAlert Mycoplasma Detection Kit (Lonza). HCT-116 and A549 cells were cultured in DMEM, and DLD1 cells were cultured in RPMI1640 supplemented with 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin at 37°C in 5% CO2. The following reagents were used: RO-3306, thymidine, chlorodeoxyuridine (CldU), iodedeoxyuridine (IdU), bromodeoxyuridine (BrdU), dTTP, BrdUTP (Sigma), FTD (Tokyo Chemical Industry), and FTD-TP (Movarek).
DNA fiber analysis
DNA fiber analysis was performed as described previously (23) with some modifications. For nascent DNA labeling, DLD1 cells were cultured in the presence of 20 µM CldU for 20 min, washed twice with fresh medium, and cultured in the presence of 20 µM IdU or 20 µM FTD for the indicated times. After double labeling, cell suspensions were spotted on slides, airdried, and lysed with cell lysis solution (200 mM Tris-HCl, pH7.5, 50 mM EDTA, and 0.5% SDS). Following cell lysis, the slides were tilted to 15 o to allow the DNA fibers to spread along the slides. After fixation with methanol/acetic acid (3:1) and DNA denaturation with 2.5 N HCl, the DNA fibers on slides were immunostained with two different anti-BrdU antibodies (Table S1) , anti-mouse IgG conjugated with Alexa Fluor 568, and anti-rat IgG conjugated with Alexa Fluor 488 (Molecular Probes) at 1:400 dilution. Slides were mounted with Vectashield (H-1000; Vector lab).
In vitro DNA polymerase assay
The proteins used for the in vitro DNA polymerase assay ( Fig. S2 ) were purified as described previously (24) (25) (26) . Human DNA polymerase d/e activity was measured with reference to the incorporation of [a- 32 To measure DNA synthesis on the oligonucleotides, the 5′ end of the oligonucleotide primer was radiolabeled with [g-32 P] ATP, annealed with the template oligonucleotide, and subjected to in vitro DNA polymerase reaction at 37°C for the indicated times. The reaction was stopped by adding a bromophenol blue/xylene cyanate-formamide EDTA solution. After boiling at 95°C for 3 min, the samples were loaded onto 15% acrylamide gels containing 7% urea and electrophoresed at 30W for 60 min. The gels were fixed with 15% methanol/15% acetate solution for 10 min, rinsed with tap water, and dried on 3MM paper. Radioactivity was detected using BAS2000 (GE Healthcare).
Quantification of dTTP, FTD-TP, and BrdUTP using liquid chromatography/triplestage quadrupole mass spectrometry (LC-QqQ-MS)
Intracellular dTTP, FTD-TP, and BrdUTP were quantified using LC-QqQ-MS as described previously (27) . FTD-TP and BrdUTP were detected with optimized selective reactionmonitoring transitions in negative ionization mode as follows: FTD-TP: precursor ion 
Generation of TP53-deficient HCT-116 cells
First, a 20-mer sgRNA target sequence (5′-CTCAGAGGGGGCTCGACGCT-3′) at exon 2 of the TP53 gene was designed (28) and cloned into pX330 (Addgene #42230), which was a gift from Dr. Feng Zhang (29) . The donor DNA plasmid was constructed from the PCR fragment [~1,300-bp of the TP53 genomic region including the sgRNA target sequence amplified by PCR (forward: 5′-ACTATATCCTTGTTAACAGGAGGTGGGAGC-3′; reverse: 5′-
AAGGGTGAAGAGGAATCCCAAAGTTCCAAAC-3′)] in pCR4-TOPO [Thermo Fisher
Scientific (hereafter, Thermo)], and its 130-bp Bam HI fragment that includes the sgRNA target sequence was replaced with the 2,500-bp Bam HI fragment containing a puromycinresistant gene cassette (30) . The above two plasmids were co-transfected into HCT-116 cells using 4D Nucleofector (Lonza). The puromycin-resistant clones were screened by genomic PCR and sequencing.
Generation of fluorescent ubiquitination-based cell cycle indicator (Fucci) expressing cells by lentiviral infection
cDNA encoding mKO2-hCdt1 (aa 30-120) or mAG1-hGeminin (aa 1-110) amplified from the pFucci-G1 Red plasmid (AM-V9003) or pFucci-S/G2/M Green plasmid (AM-V9016) (MBL), respectively, was cloned into the pENTR D-TOPO vector (Thermo). Each plasmid was mixed with pLenti6.4⁄R4R2⁄V5-DEST and pENTR 5′/EF1αP and recombined using LR Clonase II Plus enzyme (Thermo). The lentiviruses were produced using the ViraPower Lentiviral Expression System (Thermo). To establish HCT-116-Fucci or HCT-116 p53 -/--Fucci cells, cells were infected with both lentiviruses encoding mKO2-hCdt1 (30-120) and mAG1-hGeminin (1-110) at a multiplicity of infection of 1 each. The infected cells were first selected by blasticidin (Thermo) treatment. The surviving cells were sorted in two steps using BD FACSAria SORP (BD Bioscience) as follows: cells emitting red fluorescence were sorted and cultured for several days, and then cells emitting green fluorescence were sorted.
Western blot analysis
Western blot analysis was performed as described previously (21) . The antibodies used are listed in Table S1 . Chemiluminescence was detected using LAS 4000 mini (GE Healthcare).
Immunofluorescence
Cells were rinsed in PBS at 37°C, fixed in 4% paraformaldehyde (PFA) for 15 min at 37°C (mitosis) (31) or 3% PFA, 2% sucrose, and 0.5% Triton X-100 for 30 min on ice (nuclear foci) (32) , permeabilized in PBS containing 0.1% Triton X-100 for 5 min at 37°C, blocked in PBS containing 2% BSA for 30 min at room temperature, and incubated for 16 h at 4°C with the antibodies listed in Table S1 . Secondary antibodies conjugated to Alexa Fluor 488, 568, or 647 (Molecular Probes) were used at 1:2,000 dilution. After washing in PBS containing DAPI for 5 min, the coverslips were mounted in ProLong Diamond or ProLong Glass (Thermo).
Image acquisition
For fixed-cell experiments, fluorescence image acquisitions were performed using a Nikon A1R confocal imaging system or N-SIM super resolution imaging system controlled by NIS Elements software (Nikon). The objective lens was an oil immersion CFI SR ApoTIRF 100× NA 1.49 lens, an oil immersion Plan-Apo 100× NA 1.45 lens, or a Plan-Apo 40× NA 0.95 lens (Nikon). Images were acquired as Z-stacks at 0.2-µm or 0.12-µm intervals with a confocal or a super-resolution microscope, respectively, and maximum-intensity projections were generated using NIS Elements software (Nikon).
For live-cell imaging of cell cycle progression, HCT-116-Fucci or HCT-116 p53 -/--Fucci cells were imaged in a chambered coverglass (Matsunami) containing phenol red-free DMEM (Gibco). Live-cell imaging was performed as described previously (31) . The duration of the cell cycle phases was calculated manually.
For the quantification of nuclear foci of FancD2 and RPA32, fluorescence images were acquired using BZ-X800 (Keyence) with Plan-Apo 40×NA, and nuclear foci were counted using Hybrid Cell Count Software (Keyence).
Animals and evaluation of antitumor activity in vivo
All animal studies were performed according to the guidelines and with the approval of the institutional Animal Care and Use Committee of Taiho Pharmaceutical Co., Ltd. Ethical approval (5 Mar 2019) was obtained prior to conducting the animal experiments. Male nude mice (CLEA Japan) were housed under specific pathogen-free conditions, with food and water provided ad libitum. The animals were quarantined for 1 week and then subcutaneously implanted with 1 × 10 7 HCT-116 or HCT-116 p53 -/cells on day 0. The mice were randomized on day 3 based on body weight and each treatment group consisted of six mice. FTD/TPI was prepared by mixing FTD and TPI at a molar ratio of 1:0.5 in 0.5% HPMC solution. FTD/TPI (FTD: 200 mg/kg/day) was administered orally twice daily from days 3-7, days 10-14, and days 17-21 at approximately 6-hour intervals. For the control group, vehicle (0.5% HPMC solution) was administered at 10 mL/kg.
Statistical analysis
The statistical analysis was performed using GraphPad Prism (GraphPad Software) or EXSUS (CAC Croit Corp.) software. The Mann-Whitney U test was used in Figs. 1B and 5C, the Kruskal-Wallis test in Fig. 3D and E, and the unpaired t-test in Figs. 4F, 4G, 6B, and 6D.
RESULTS
FTD stalls replication forks and activates the DNA damage response
In a previous study, we showed that FTD induces pS345 Chk1, an indicator of the DNA damage response to DRS, during its misincorporation into DNA (21) . We hypothesized that the process of FTD misincorporation itself would cause DRS, and FTD-containing replication fork progression would be retarded. To evaluate the speed of individual active replication forks, we performed DNA fiber analysis (23) . Active elongating replication forks were labeled with CldU, and their elongation was measured by subsequent labeling with IdU or FTD ( Fig. 1A and B ) because IdU and FTD are recognized by B44 but not by BU1/75 ( Fig. S1A and B) (33) . FTD-containing forks were significantly shorter than IdU-containing replication forks ( Fig. 1A and B ). Furthermore, FTD, but not CldU or IdU, induced pS345 Chk1 (Fig. 1C) . These results indicate that FTD stalled replication forks during its incorporation into DNA and activated the DNA damage response.
FTD impedes replicative DNA polymerases in vitro
We hypothesized that FTD triphosphate (FTD-TP) would be incorporated into DNA during replication catalyzed by replicative DNA polymerases (Pold and Pole) with low efficiency, which could slow the elongation of the nascent DNA strand. To test this possibility, DNA synthesis was evaluated by measuring the incorporation of radioactive [a-32 P] dATP in an in vitro reconstituted DNA replication assay using purified proteins ( Fig. S2A-2C ). The [a- 32 P] dATP incorporation rate was significantly lower in the presence of FTD-TP than in the presence of dTTP or BrdUTP (Fig. 1D ). In addition, the low [a-32 P] dATP incorporation rate in the presence of FTD-TP was almost completely rescued when 50% of FTD-TP was replaced by dTTP ( Fig. 1E) . These results indicate that the incorporation rate of FTD-TP into the nascent DNA strand was less efficient than that of dTTP or BrdUTP.
To identify the specific sequence in the template DNA strand at which the synthesis of the nascent DNA strand is impeded in the presence of FTD-TP, we performed an in vitro DNA replication assay with a defined DNA template. Synthesis of the nascent DNA strand in the presence of FTD-TP was strongly and specifically impeded at positions of repetitive adenine sequences ( Fig. 1F ), whereas synthesis was only slightly impeded at positions of dispersed adenine sequences ( Fig. S3 ).
We further examined whether the elongation of the nascent DNA strand was retarded when Pold and Pole encounter FTD in the template DNA strand. Elongation was significantly suppressed when either Pold or Pole was used to replicate a template DNA strand containing five repetitive FTDs at the 3′ vicinity of the primer end ( Fig. 1G ). Collectively, these results indicate that FTD induced DRS by impeding the progression of replicative DNA polymerases during its incorporation into the nascent strand DNA as well as when FTD was present in the template DNA strand.
FTD addition rapidly decreases dTTP and increases FTD-TP in the cellular dNTP pool
Next, we examined whether FTD-TP was generated when cells were cultured in the presence of FTD. In HCT-116 cells cultured in the presence of various concentrations of FTD for 60 min, FTD incorporation was detected (Fig. S4A ), and dTTP decreased and FTD triphosphate (FTD-TP) increased in a concentration-dependent manner ( Fig. S4B and C) . In HCT-116 cells cultured in the presence of FTD, dTTP decreased rapidly (in 30 min) as FTD-TP increased in the cellular dNTP pool ( Fig. 2A and B ). At this time point, FTD was being continuously incorporated into DNA (Fig. 2C ) and induced pS345 Chk1 (Fig. 2D ). When FTD was removed from the medium, dTTP recovered rapidly as FTD-TP disappeared from the dNTP pool ( Fig. 2E and F) . These data indicate that FTD-TP was generated when cells were cultured in the presence of FTD and that it activated the DNA damage response during its incorporation into DNA.
DNA lesions including ssDNA are generated as a result of FTD-induced replication fork stalling
Next, we monitored cellular responses in HCT-116 cells cultured in the presence of FTD. At 24 h, FTD induced pS345 Chk1 and FancD2 monoubiquitination (Fig. 3A) , indicating activation of ATR kinase and the Fanconi anemia DNA repair pathway in response to stalled replication forks. Consistently, major populations of cells were in S phase at 24 h (Fig. 3B) .
At 48 h, when most cells showed 4N DNA content (Fig. 3B) , however, pS345 Chk1 and FancD2 monoubiquitination had decreased and p53 and p21 had increased (Fig. 3A) . This result suggests that FTD transiently stalled replication forks and activated the ATRdependent DNA damage response, which in turn triggered activation of the p53-p21 pathway probably via DNA lesions arising from improperly processed stalled replication forks.
Failure to complete DNA replication during S phase produces ssDNA-containing UR-DNA, which leads to DNA lesions that are transmitted across cell generations if they are not repaired properly (34) (35) (36) . To investigate whether FTD generated ssDNA, we coimmunostained the ssDNA binding protein RPA32 and FancD2 in FTD-treated HCT-116 cells (Fig. 3C ). We observed a modest increase of RPA32 nuclear foci at 24 h, when pannuclear FancD2 foci were formed. At 48 h, however, when only a small number of FancD2 nuclear foci were observed, the number and intensity of RPA32 nuclear foci increased dramatically ( Fig. 3D and E) . These data suggest that FTD generated ssDNA that persisted because of replication fork stalling.
FTD induces senescence in tumor cells with wild-type p53 and apoptosis in p53 knockout tumor cells
We previously showed that FTD induces p53-dependent sustained cell cycle arrest at the phase with 4N DNA content (21) . To elucidate the role of p53 in the FTD-induced DNA damage response, we generated isogenic TP53 gene knock-out HCT-116 cell lines using the CRISPR/Cas9 system (Fig. S5 ). In the presence of FTD, cell proliferation was similarly suppressed in HCT-116 and HCT-116 p53 -/cells until day 3. In HCT-116 cells, proliferation ceased completely on day 6, and cell number did not change until day 9. However, in HCT-116 p53 -/cells, cell number started to decrease after day 3 and most cells had disappeared by day 9 (Figs. 4A and S6) . The same results were obtained when FTD was removed from the cell culture media of both cell lines on day 3 (Fig. 4A ), indicating that cell fate was determined before day 3.
We next examined the cellular response to FTD in HCT-116 and HCT-116 p53 -/cells ( Fig.   4B ). HCT-116 cells showed accumulation of p53 and p21 and almost undetectable expression of cyclin B1 and cyclin A proteins on day 3 at the time when accumulation of cyclin D1 was observed ( Fig. 4B ), suggesting that a significant proportion of cells were in G1 phase. In HCT-116 p53 -/cells, however, p21 and cyclin D1 did not accumulate, and cyclin B1 and cyclin A levels did not decrease (Fig. 4B ). Furthermore, similar results were obtained using A549 (p53 wild type) and DLD1 (p53 mutant) cells ( Fig. S7A-C) . These data indicate that FTD activated the p53-p21 pathway and suppressed the growth of cells expressing wild-type p53, resulting in the accumulation of cells in G1 phase, whereas in cells without p53, FTD caused tumor cell death.
Chronic DRS activates p53 and induces cellular senescence-like growth arrest (14) .
Consistently, on day 3 of FTD treatment, most HCT-116 cells were senescence-associated bgalactosidase (SA-b-gal)-positive, whereas only a limited population of HCT-116 p53 -/cells showed this phenotype (Fig. 4C) . Similar results were obtained with A549 and DLD1 cells ( Fig. S7D ). By contrast, on day 6 of FTD treatment, the number of cells in the sub-G1 population was greater in HCT-116 p53 -/cells than in HCT-116 cells (Fig. 4D) . Immunoblot analysis showed a dramatic upregulation of markers of DNA damage (gH2AX) and apoptosis (cleaved PARP and caspase 3) in HCT-116 p53 -/cells, but not in HCT-116 cells (Fig. 4E) .
These data indicate that cellular senescence and apoptotic cell death were predominantly induced in FTD-treated HCT-116 and HCT-116 p53 -/cells, respectively.
Lastly, we examined the effect of tumor p53 status on the response to FTD/TPI treatment in an in vivo xenograft mouse model. FTD/TPI treatment significantly suppressed the growth of HCT-116 and HCT-116 p53 -/xenograft tumors ( Fig. 4F and G) , indicating that FTD/TPI exerts its tumor suppressive effect irrespective of p53 status.
Cell fate is determined according to p53 status at the G2/M transition following an
FTD-induced extended S/G2 phase
We showed that FTD treatment determined cell fate in a p53-dependent manner. To explore this phenomenon in detail, time-lapse analysis of HCT-116 and HCT-116 p53 -/cells was performed using the Fucci system to visualize cell cycle status (37) . DNA damage-induced cellular senescence-like G1 phase arrest proceeds via mitosis skip, which is a G2-to-G1 phase transition without mitotic cell division (38) . Consistent with this finding and the results of the SA-b-gal assay in HCT116 cells (Fig. 4C ), most HCT116-Fucci cells showed a mitosis skip phenotype, whereas a minor proportion of HCT116-Fucci cells displayed G1 phase arrest after normal mitosis in response to FTD treatment ( Fig. 5A and B ). Furthermore, although HCT116 p53 -/cells entered mitosis, the duration of mitosis was severely extended, and cells exited mitosis and entered the next G1 phase without separation into daughter cells ( Fig. 5A-C ). Intriguingly, FTD treatment markedly extended the duration of the second S/G2 phase rather than the first S/G2 phase in both HCT-116 and HCT-116 p53 -/cells ( Fig. 5B and C) .
Collectively, these data indicate that FTD treatment specifically slows the progression of S/G2 phase irrespective of p53 status, although p53 is specifically involved in cell fate determination at the G2/M phase transition after the second G2 phase.
Severe chromosomal bridges are induced by FTD during late mitosis in p53-null cells
Upon mild perturbation of DNA replication, sister chromatids are frequently interlinked at fragile sites, which are located at genetic loci with intrinsic replication difficulties, by BLM/PICH-associated UFBs (12) . We thus investigated whether FTD affects the formation of sister chromatid interlinks. First, to evaluate the effect of FTD treatment at the first S/G2 phase on sister chromatid separation in the following anaphase, HCT-116 p53 -/cells were exposed to FTD in the presence of RO-3306, a Cdk1 inhibitor that perturbs the G2 to M phase transition (39) , and then released into mitosis in fresh medium for 50 min to enrich anaphase cells (Fig. 6A ). Most anaphase cells showed separation of sister chromatids to the spindle poles; however, the appearance of PICH-associated UFBs, most of which also contained chromosomal bridges, was also significantly increased (Fig. 6B) . These results indicate that FTD treatment-induced DRS during FTD-TP incorporation into nascent DNA strands partially disturbed the separation of several individual sister chromatids, it was not strong enough to prevent the process of chromosome segregation.
Next, we observed anaphase chromosomes during the second mitosis in the presence of FTD, most of which incorporated FTD into the template DNA strand. HCT-116 p53 -/cells were exposed to FTD for 60 h, and chromosomal structures were observed in anaphase. To differentiate anaphase cells with unseparated sister chromatids from prometaphase cells, cells were immunostained for cyclin B1, and only cyclin B1-negative cells that had already proceeded into anaphase were evaluated (Fig. S8 ). Most anaphase cells showed no separation of sister chromatids to the spindle poles ( Fig. 6C and D) . In addition, super-resolution microscopy of centromere and microtubule staining showed that each kinetochore was captured by mitotic spindles (Fig. 6C, insets 4-6 ), similar to kinetochores with sister chromatids separated to the spindle poles as observed in normal anaphase cells (Fig. 6C,   insets 1 and 2) . Furthermore, closer observation of each chromosome revealed that a significant population of sister chromatid pairs showed interlinking along chromosomal arms ( Fig. 6C, inset 3) , whereas the corresponding sister kinetochores were captured by spindles from the opposite spindle poles and were already separated (Fig. 6C, inset 4) . These data indicate that, upon severe DRS induced by FTD treatment during the second S phase, p53 knock-out cells displayed severe defects in sister chromatid separation at anaphase, but not in the capture of kinetochores by spindles.
DISCUSSION
In this study, we elucidated the mechanism underlying tumor cytotoxicity induced by the fluorinated thymidine analog-type chemotherapeutic drug, FTD. FTD treatment replaced dTTP in the dNTP pool with FTD-TP, which slowed DNA synthesis by replicative DNA polymerases. Thus, FTD slowed DNA replication fork progression and subsequently generated DNA lesions, including ssDNA, and activated p53, thereby inducing cellular senescence. In the absence of p53, FTD triggered apoptotic cell death by inducing aberrant mitosis associated with severely unseparated sister chromatids. Because tumor cells show high levels of DRS and depend on their response to DRS, exploiting DRS is a feasible approach for cancer therapy (3) (4) (5) . As a chemotherapeutic drug, FTD is ideal because it exacerbates cellular DRS to exert cytotoxic effects irrespective of p53 status (Fig. 7) . however, the incorporation of FTD-TP was not efficient. Another intriguing property of FTD-TP is that FTD incorporation did not terminate DNA polymerization, allowing its continuous incorporation into DNA to produce FTD-containing DNA strands. By contrast, other chemotherapeutic agents, such as gemcitabine and cytarabine, terminate DNA polymerization in the vicinity of their incorporation (16) and are incorporated into DNA to a lower extent than FTD (40) . Second, as a component of the template DNA strand, FTD constitutes a continuous obstacle to DNA polymerization. This property may explain the severe extension of the second S/G2 phase after FTD addition, because DNA synthesis at the second S phase would have to proceed with the FTD-containing template DNA strand in the presence of FTD-TP in the dNTP pool. Third, FTD incorporated into the DNA of tumor cells is retained for a prolonged period (41) . This property would cause persistent disturbance of the replication process and tumor cytotoxicity, which may underlie the sustained growth suppressive effect and prolonged survival observed in a xenograft mouse model exposed to limited courses of FTD/TPI (40) . The dual perturbation of DNA replication caused by the inefficient incorporation of FTD during DNA synthesis and the persistent roadblock, which represents FTD incorporated into template DNA strand, for DNA polymerization are probably key properties underlying the success of this chemotherapeutic drug.
Because FTD is a thymidine analog, inefficient DNA replication occurs preferentially at ATrich genomic loci, e.g. CFSs (42) . FTD would enhance DRS at these fragile sites and exacerbate DNA lesions resulting from the generation of UR-DNA. However, our previous study did not detect an increase in DNA strand breaks in FTD-treated HCT-116 cells (21) .
DNA lesions such as UR-DNA with FTD incorporation at CFSs could be protected by proteins that accumulate at these lesions, such as FancD2 and the RPA complex, as suggested by the formation of discrete FancD2 and RPA32 nuclear foci (Fig. 3C) , and result in the activation of the p53-p21 pathway to avoid catastrophic collapse of chromosomes (14) .
On the other hand, in p53 knock-out cells, such DNA lesions were probably converted to detrimental DNA strand breaks, as evidenced by the detection of gH2AX (Fig. 4E) , through aberrant mitosis progression and unseparated sister chromatids probably caused by interlinks between UR-DNA located at chromosomal arms (Fig. 6 ).
In this study, cellular analysis revealed that FTD suppresses the growth of tumor cells irrespective of p53 status. p53-dependence diverged at the second G2/M phase transition, resulting the redirection of cell fate toward either cellular senescence or apoptotic cell death.
p53-mediated senescence, however, impairs the apoptotic response to chemotherapy, and the senescent tumor cells show persistent mitogenic potential, which causes relapse (43) . Recent studies indicate that establishment of senescence may reprogram tumor cells into a latent stem-like state, resulting in tumor cells that escape senescence having a more aggressive 21 phenotype (44, 45) . Because FTD is a component of the chemotherapeutic drug FTD/TPI (18) (19) (20) , it is critical to determine whether FTD-induced senescent tumor cells also acquire stemness and a persistent mitogenic potential. If that is the case, a strategy for evading FTDinduced senescence or for directing tumor cell fate toward apoptotic death should be given serious consideration.
FTD/TPI shows efficacy in the treatment of colorectal cancer patients who are refractory or intolerant of 5-FU-based therapy (17) (18) (19) . At the cellular level, acquired resistance to 5-FU does not confer FTD resistance and vice versa (22, 46, 47) , possibly reflecting the distinct mechanism of action of each drug. The unique and distinct property of FTD demonstrated in this study may expand the clinical application of FTD-based therapy. Additionally, gain-offunction mutations or heterozygous mutations are frequently found in the TP53 gene locus of tumors obtained from patients (48) . Therefore, investigating whether the expression of mutant p53 affects the cellular response and tumor cell fate decision induced by FTD is an important issue. 
